Journey Medical Corp (DERM)
3.69
+0.06
(+1.65%)
USD |
NASDAQ |
May 03, 16:00
3.68
-0.01
(-0.27%)
Pre-Market: 20:00
Journey Medical Research and Development Expense (Quarterly): 1.505M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.505M |
| September 30, 2023 | 2.229M |
| June 30, 2023 | 1.774M |
| March 31, 2023 | 2.033M |
| December 31, 2022 | 4.256M |
| September 30, 2022 | 2.812M |
| June 30, 2022 | 2.609M |
| March 31, 2022 | 1.266M |
| Date | Value |
|---|---|
| December 31, 2021 | 1.992M |
| September 30, 2021 | 0.794M |
| June 30, 2021 | 13.77M |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
Jun 2020
13.77M
Maximum
Jun 2021
2.336M
Average
1.774M
Median
Jun 2023
Research and Development Expense (Quarterly) Benchmarks
| Fortress Biotech Inc | 14.08M |
| Puma Biotechnology Inc | 12.87M |
| GT Biopharma Inc | 1.357M |
| FibroGen Inc | 51.70M |
| Outlook Therapeutics Inc | 4.529M |